Signaling, Delivery and Age as Emerging Issues in the Benefit/Risk Ratio Outcome of tPA For Treatment of CNS Ischemic Disorders

Stroke is a leading cause of morbidity and mortality. While tissue-type plasminogen activator (tPA) remains the only FDA approved treatment for ischemic stroke, clinical use of tPA has been constrained to roughly 3% of eligible patients because of the danger of intracranial hemorrhage and a narrow 3...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Armstead, William M, Ganguly, Kumkum, Kiessling, JW, Riley, John, Chen, Xiao-Han, Smith, Douglas H, Stein, Sherman C., Higazi, Abd AR, Cines, Douglas B, Bdeir, Khalil, Zaitsev, Sergei, Muzykantov, Vladimir R.
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3467975/
https://ncbi.nlm.nih.gov/pubmed/20405577
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы